InnoCare Pharma (HKG:9969, SHA:688428) unit Beijing InnoCare Pharma Tech and certain other parties have entered into an exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02, a Monday Hong Kong bourse filing said.
The contract grants Prolium the exclusive right to develop, register, manufacture, and commercialize ICP-B02 globally in non-oncology fields and in global oncology fields outside of Asia.
ICP-B02 is designed to redirect and activate T-cells to eliminate tumor cells through T-cell Dependent Cellular Cytotoxicity and is undergoing clinical trials to assess its safety and efficacy.
Beijing InnoCare Pharma Tech and Keymed Biosciences' (HKG:2162) unit Keymed Biosciences (Chengdu) each own 50% rights in ICP-B02, with future revenue to be shared equally between the parties.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.